# Supplemental Information

#### **1.1 SUPPLEMENTARY FIGURES**







Figure S-1. Estimated deconvolution of observed 8-hour GH levels associated with each of the 14 participants from Dataset 1. Each panel shows the simulated 8-hour GH time series (red crosses), the model-estimated GH levels (black curve) and the model-estimated pulse timing and amplitude (blue vertical lines) for a single participant. The estimated model parameters are provided in Table 1 in the main text.



Figure S-2. Estimated deconvolution of observed 8-hour GH levels associated with each of the 4 participants from Dataset 2. Each panel shows the simulated 8-hour GH time series (red crosses), the model-estimated GH levels (black curve) and the model-estimated pulse timing and amplitude (blue vertical lines) for a single participant. The estimated model parameters are provided in Table 2 in the main text.





Figure S-3. Estimated deconvolution of simulated 8-hour GH levels associated with each of the 14 participants from Dataset 1 at a SNR of 20 dB. Each panel shows the simulated 8-hour GH time series (red crosses) generated from the "ground truth" pulse timing and amplitude (green vertical lines), the model-estimated GH levels (black curve), and the estimated pulse timing and amplitude (blue vertical lines) for a single participant. The estimated model parameters are provided in Table 3 in the main text.



Figure S-4. Estimated deconvolution of simulated 8-hour GH levels associated with each of the 4 participants from Dataset 2 at a SNR of 20 dB. Each panel shows the simulated 8-hour GH time series (red crosses), generated from the "ground truth" pulse timing and amplitude (forest green vertical lines), the model-estimated GH levels (black curve), and the model-estimated pulse timing and amplitude (blue vertical lines) and the ground truth pulse timing and amplitude (green vertical lines) for a single participant. The estimated model parameters are provided in Table 4 in the main text.

r

### **1.2 LISTWISE DELETION**

If there are missing values in the GH time series data, then subsequent analyses must be suitable for both our proposed algorithm and the missingness of the data.

In our estimation algorithm, we apply a least squares approach, modelling v<sub>i</sub> as a Gaussian random variable, where  $v_i = y_i - F_{\beta_i} H_d[0] - D_{\beta_i} u_i$  and  $i = \{1, 2, 3, \dots, M\}$ . We can represent the probability density function of  $v_i$  as  $P_1(v_i | \sigma^2)$ where  $P_1(v_i | \sigma^2) = \frac{1}{\sqrt{2\sigma^2}} e^{\frac{V \cdot U}{2\sigma^2}}$ . Assuming the missing GH data are randomly distributed, we then represent the probability density function of missing values as  $P_2(x)$  with unknown parameters denoted x. If the probability density function of a missing response,  $P_2(x)$ , is unrelated to the either the actual value missing from the data or the set of observed responses, then that response is said to be Missing Completely At Random (MCAR) [1]. Furthermore, if the set of missing responses is MCAR, then the likelihood function of  $P_1$  and  $P_2$  can be represented as  $P_1(v_i|\sigma^2)$ .  $P_2(x)$ . We take the negative log of the likelihood function of  $P_1$  and  $P_2$ , resulting in

$$-\log(P_1(v_i|\sigma^2)) - \log(P_2(x))$$
  
=  $\frac{1}{2\sigma^2} ||y_i - F_{\beta_i}H_d[0] - D_{\beta_i}u_i||_2^2 - \log(P_2(x))$  (17)

We can see in (17) that the Gaussian distribution of measurement error is independent from the uniform distribution of missing values. The distribution of missing values does not depend on observed data and as such the missing data is considered MCAR.

We perform listwise deletion, as opposed to imputation, because (i) the temporal resolution of our GH data does not lend itself to imputation, (ii) listwise deletion will yield an unbiased estimate of mean response trends, because the missingness of GH data is MCAR [1], and (iii) our proposed algorithm accounts for missing sample data. Additionally, methods of imputation like linear interpolation tend to produce biased estimates of parameters [2].

We perform listwise deletion by reformulating the optimization problem in (12) as:

$$\min \frac{1}{2} \sum_{i \in \{1,2,\cdots,M\} \setminus \{S\}}^{M} (y_i - F_{\beta_i} H_d[0] - D_{\beta_i} u_i)^2$$
(18)

where **S** represents the set of indices in which sample data is missing.

Listwise deletion introduces no bias in the

approximation of model parameters or of the timing and amplitude of secretory events. Therefore, maximizing the fit of available data via our estimation algorithm also improves the estimation of missing data, where  $y_j = F_{\beta_j}H_d[0] + D_{\beta_j}u_j$  and  $j \in \{S\}$ .

#### **1.3 PARTICIPANT INFORMATION**

The sex, age, and BMI of each participant from Dataset 1 are listed in Table S-1. The sex, age, BMI and Apnea-Hypopnea Index (AHI) for each participant from Dataset 2 are in Table S-2.

Participant No.	Sex	Age [years]	$BMI\left[\frac{kg}{m^2}\right]$
1	F	12.5	18.6
2	F	12.3	19.2
3	F	12.3	17.9
4	F	11.6	16.5
5	F	12.3	19.8
6	М	13.4	17.9
7	F	13.4	20.5
8	F	13.2	25
9	М	11.3	26.1
10	М	12.0	22.9
11	М	12.2	29.3
12	М	13.8	18.7
13	М	13.4	17.9
14	М	14.1	21.6

TABLE S-1
PARTICIPANT SEX, AGE AND BMI FOR DATASET 1

TABLE S-2 PARTICIPANT SEX, AGE AND BMI FOR DATASET 2.

Participant No.	Sex	Age [years]	$BMI\left[\frac{kg}{2}\right]$	AHI	
			Lm²J	off cpap	on cpap
1	F	12.3	25.9	5.4	4.1
2	М	14.4	40.4	2.2	0.2
3	М	13.4	18.2	1.2	0.0
4	М	11.8	14.9	0.0	0.0

## **1.4 ALTERNATIVE METHOD: PEAK DETECTION**

We used the *findpeaks*() function within MATLAB for detecting secretion events. We apply the relevant constraints of our problem (i.e., the maximum number of secretory events) to estimate a physiologically plausible solution and the minimum distance between secretory events based on this constraint in our method. While this peak detection method can identify significant peaks in serum GH data, it cannot recover the model parameters or accurate GH pulse locations, because this method lacks a physiological interpretation of GH secretion. This peak detection method also does not provide the infusion and clearance rates. Additionally, the location of serum GH peaks identified by the peak detection method is not the location of the GH secretion event. Rather, the peak detection provides the location of the maximum level of serum GH after a secretion event. This peak detection method also identified two small noise spikes (near 0 and 6.5 hours) as a GH peak, as indicated in Figure S-5.



Figure S-5. Detected peaks of Participant 1-1 (red crosses) and the experimental GH data (black curve).

#### REFERENCES

- [1] M. Nakai and W. Ke, "Review of Methods for Handling Missing data in Longitudinal Data Analysis," *International Journal of Mathematics Analysis*, vol. 5, pp. 1-13, 2011.
- [2] P. D. Allison, Missing Data Quantitative applications in the social sciences, Thousand Oaks, CA: Sage, 2001.
- [3] S. Hiller-Sturmhöfel and A. Bartke, "The Endocrine System: An Overview," *Alcohol Health and Research World*, vol. 22, no. 3, pp. 153-162, 1998.
- [4] Y. Kato, Y. Murakami, M. Sohmiya and M. Nishiki, "Regulation of Human Growth Hormone Secretion and its Disorders," *Internal Medicine*, vol. 41, no. 1, pp. 7-13, 2002.
- [5] N. Møller and J. O. L. Jørgensen, "Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects," *Endocrine Reviews*, vol. 30, no. 2, pp. 152-177, 2009.
- [6] S. Kim and M. Park, "Effects of growth hormone on glucose metabolism and insulin resistance in human," *Annals of Pediatric Endocrinology & Metabolism*, vol. 22, pp. 145-152, 2017.
- [7] P. E. Mullis, B. R. Pal, D. R. Matthews, P. C. Hindmarsh, P. E. Phillips and D. B. Dunger, "Half-life of exogenous growth hormone following suppression of endogenous growth hormone secretion with somatostatin in type I (insulindependent) diabetes mellitus," *Clinical Endocrinology*, vol. 36, no. 3, 1992.
- [8] E. B. Klerman, G. K. Adler, M. Jin, A. M. Maliszewski and E. N. Brown, "A statistical model of diurnal variation in human growth hormone," *American Journal of Physiology*, vol. 285, no. 5, pp. E1118-E1126,

2003.

- [9] K. Gunawardane, T. K. Hansen, N. Muller, J. S. Christiansen and J. O. L. Jorgensen, "Normal Physiology of Growth Hormone in Adults," NCBI, 12 November 2015. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBH279056. [Accessed 2 July 2019].
- [10] J. D. Veldhuis and A. Iranmanesh, "Physiological Regulation of the Human Growth Hormone (GH)-Insulin-Like Growth Factor Type I (IGF-I) Axis: Predominant Impact of Age, Obesity, Gonadal Function, and Sleep," *American Sleep Disorders* Association and Sleep Research Society, vol. 19, no. 10, pp. S221-S224, 1996.
- [11] F. Kimura and C. W. Tsai, "Ultradian rhythm of growth hormone secretion and sleep in the adult male rat," *The Journal of Physiology*, vol. 353, pp. 305-315, 1984.
- [12] K. Y. Ho, J. D. Veldhuis, M. L. Johnson, R. Furlanetto, W. S. Evans, K. G. M. M. Albert and M. O. Thorner, "Fasting Enhances Growth Hormone Secretion and Amplifies the Complex Rhythms of Growth Hormone Secretion in Man," *The American Society for Clinical Investigation, Inc.*, vol. 81, pp. 968-975, 1988.
- [13] G. V. D. Berg, M. F. J. D. Veldhuis and F. Roelfsema, "An Amplitude-Specific Divergence in the Pulsatile Mode of Growth Hormone (GH) Secretion Underlies the Gender Differemce in Mean GH Concentrations in Men and Premenopausal Women," *Journal of Clinical Endocrinology and Metabolism*, vol. 81, no. 7, pp. 2460-2467, 1996.
- [14] M. L. Vance, J. Rivier and M. O. Thorner, "Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.," *The Journal of Clinical Investigation*, vol. 75, no. 5, pp. 1584-1590, 1985.
- [15] E. V. Cauter, L. Plat and G. Copinschi, "Interrelations Between Sleep and the Somatotropic Axis," *SLEEP*, vol. 21, no. 6, pp. 553-566, 1998.
- [16] E. V. Cauter and L. Plat, "SESSION III: SPONTANEOUS GROWTH HORMONE SECRETION AND THE DIAGNOSIS OF GROWTH HORMONE DEFICIENCY," *The Journal of Pediatrics*, vol. 125, no. 5, Part 2, pp. S32-S37, 1996.
- [17] Y. Takahashi, D. M. Kipnis and W. H. Daughaday, "Growth Hormon Secretion during Sleep," *The Journal of Clinical Investigation*, vol. 47, no. 9, pp. 2079-2090, 1968.
- [18] R. T. Faghih, "From physiological signals to pulsatile dynamics: a sparse system identification approach," in *Dynamic Neuroscience*, Springer, 2018, pp. 239-265.
- [19] R. T. Faghih, "System identification of cortisol secretion," Massachusetts Institute of Technology, 2014.
- [20] R. T. Faghih, M. A. Dahleh, G. K. Adler, E. B. Klerman

and E. N. Brown, "Deconvolution of Serum Cortisol Levels by Using Compressed Sensing," *PloS one,* vol. 9, no. 1, 2014.

- [21] R. T. Faghih, M.-F. M. P. A. Stokes, R. G. Zsido, S. Zorowitz, B. L. Rosenbaum, H. Song, M. R. Milad, D. D. Dougherty, E. N. Eskandar and e. al., "Characterization of Fear Conditioning and Fear Extinction by Analysis of electrodermal activity," in *Engineering in Medicine and Biology Society (EMBC)*, 2015 37th Annual International Conference of the IEEE, 2015.
- [22] M. R. Amin and R. T. Faghih, "Sparse Deconvolution of Electrodermal Activity via Continuous-Time System Identification," *IEEE Transactions on Biomedical Engineering*, 2019.
- [23] M. Marino, Y. Li, M. N. Rueschman, J. W. Winkelman, J. M. Ellenbogen, J. M. Solet, H. Dulin, L. F. Berkman and O. M. Buxton, "Measuring Sleep: Accuracy, Sensitivity, and Specificity of Wrist Actrigraphy Compared to Polysomnography," *SLEEP*, vol. 36, no. 11, pp. 1747-1755, 2013.
- [24] M. Barnes, R. D. McEvoy, S. Banks, N. Tarquinio, C. G. Murray, N. Vowels and R. J. Pierce, "Efficacy of Positive Airway Pressure and Oral Appliance in Mild to Moderate Obstructive Sleep Apnea," *American Journal of Respiratory and Critical Care Medicine*, vol. 170, no. 6, 2004.
- [25] E. Dehlink and H. Tan, "Update on paediatric obstructive sleep apnoea," *Journal of Thoracic Disease*, vol. 8, no. 2, pp. 224-235, 2016.
- [26] R. Nass, A. A. Toogood, P. Hellmann, E. Bissonette, B. Gaylinn, R. Clark and M. O. Thorner, "Intracerebroventricular Administration of the Rat Growth Hormone (GH) Receptor Antagonist G118R Stimulates GH Secretion: Evidence for the Existence of Short Loop Negative Feedback of GH," *Journal of Neuroendocrinology*, vol. 12, pp. 1194-1199, 2000.
- [27] M. Bidlingmaier and P. Freda, "Measurement of human growth hormone by immunoassays: Current status, unsolved problems and clinical consequences," *Elsevier*, vol. 20, pp. 19-25, 2009.
- [28] Z. Zadik, S. A. Chalew, R. J. M. Jr., M. Meistas and A. A. Kowarski, "The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals," *Journal of Clinical Endocrinology* and Metabolism, vol. 60, no. 3, pp. 513-6, 1985.
- [29] J. Murray, Visual Recognition, Inference and Coding Using Learned Sarse Overcomplete Representations, San Diego: University of California, 2005.
- [30] G. Golub, M. Heath and G. Wahba, "Generalized Cross-Vaidation as a Method for Choosing a Good Ridge Parameter," *Technometrics*, vol. 21, no. 2, pp. 215-223, 1979.
- [31] B. C. Nindl, W. C. Hymer, D. R. Deaver and W. J. Kraemer, "Growth hormone pulsality profile characteristics following acute heavy resistance exercise," *Journal of Applied Physiology*, pp. 163-172,

2001.

- [32] J. Van Helden, D. Hermsen, N. Von Ahsen and M. Bidlingmaier, "Performance evaluation of a fully automated immunoassay for the detection of human growth hormone on the Elecsys immunoassay system.," *Clinical Laboratory*, vol. 60, no. 10, pp. 1641-1651, 2014.
- [33] O. Parlak, S. T. Keene, A. Marias, V. F. Curto and A. Salleo, "Moleularly selective nanoporous membranebased wearable organic electrochemical device fro noninvasive cortisol sensing," *Science Advances*, vol. 4, no. 7, 2018.